Literature DB >> 7288216

Tetanus toxoid: what determines reaction proneness?

L Levine, G Edsall.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 7288216     DOI： 10.1093/infdis/144.4.376

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  9 in total

1.  Statement on vaccination of children with inadequate immunization records.

Authors: 
Journal:  CMAJ       Date:  1990-08-15       Impact factor: 8.262

2.  Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.

Authors:  Yufei Wang; Wanbo Tai; Jie Yang; Guangyu Zhao; Shihui Sun; Chien-Te K Tseng; Shibo Jiang; Yusen Zhou; Lanying Du; Jimin Gao
Journal:  Hum Vaccin Immunother       Date:  2017-03-09       Impact factor: 3.452

3.  Improving tetanus prophylaxis in the emergency department: a prospective, double-blind cost-effectiveness study.

Authors:  Muriel Stubbe; Luc J M Mortelmans; Didier Desruelles; Rohnny Swinnen; Marc Vranckx; Edmond Brasseur; Philippe E Lheureux
Journal:  Emerg Med J       Date:  2007-09       Impact factor: 2.740

4.  Use of reminders to increase compliance with tetanus booster vaccination.

Authors:  W W Rosser; B G Hutchison; I McDowell; C Newell
Journal:  CMAJ       Date:  1992-03-15       Impact factor: 8.262

5.  Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis.

Authors:  D J Balestra; B Littenberg
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

Review 6.  Cost-effectiveness of primary tetanus vaccination among elderly Canadians.

Authors:  B G Hutchison; G L Stoddart
Journal:  CMAJ       Date:  1988-12-15       Impact factor: 8.262

7.  [Vaccination: 1982 status].

Authors:  C Herzog; M Just
Journal:  Soz Praventivmed       Date:  1982-09

8.  Plausible blockers of Spike RBD in SARS-CoV2-molecular design and underlying interaction dynamics from high-level structural descriptors.

Authors:  Sankar Basu; Devlina Chakravarty; Dhananjay Bhattacharyya; Pampa Saha; Hirak K Patra
Journal:  J Mol Model       Date:  2021-05-31       Impact factor: 1.810

9.  Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial.

Authors:  David W Scheifele; Marc Dionne; Brian J Ward; Curtis Cooper; Otto G Vanderkooi; Yan Li; Scott A Halperin
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.